The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
Objectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML, (including AML patients with treatment-related and ELN-...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2350319 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1846126625254539264 |
---|---|
author | Fei Xin Yan-Hui Yu Xu-Liang Shen Guo-Xiang Zhang |
author_facet | Fei Xin Yan-Hui Yu Xu-Liang Shen Guo-Xiang Zhang |
author_sort | Fei Xin |
collection | DOAJ |
description | Objectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML, (including AML patients with treatment-related and ELN-adverse risk disease (n = 50)). These patients were treated with venetoclax and hypomethylating agents and HAG regimens, respectively.Results: Twenty-nine patients newly diagnosed with acute myeloid leukemia were treated with VEN-HMA (venetoclax-hypomethylating agent), while 23 patients were treated with HAG. The median age of the VEN-HMA group was 70 years, while the HAG group had a median age of 69 years. The VEN-HMA group achieved a significantly higher rate of complete remission (82.7%) compared to the cohort treated with the HAG regimen (21.7%) (P < 0.001). At the same time, the VEN-HMA group exhibited a significant survival advantage compared to the HAG treatment group(HR = 0.328, 95%CI: 0.158-0.683, P = 0.003).In patients with relapsed and refractory acute myeloid leukaemia, 43.8% of patients in the VEN-HMA treatment group achieved complete remission, which was similar to the 50% in the HAG treatment group (P > 0.99). The median overall survival was similar between the VEN-HMA and HAG groups, with 4 and 3.67 months, respectively (P = 0.290).Conclusions: In conclusion, our analyses indicated that VEN-HMA resulted in better therapeutic outcomes compared to HAG for newly diagnosed AML patients, with higher rates of complete remission and overall survival. In relapsed/refractory AML patients, there was no significant difference in the efficacy of the two treatments and further studies with larger sample sizes are warranted. |
format | Article |
id | doaj-art-0fab1d27c82c44a88981bded59d4a223 |
institution | Kabale University |
issn | 1607-8454 |
language | English |
publishDate | 2024-12-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Hematology |
spelling | doaj-art-0fab1d27c82c44a88981bded59d4a2232024-12-12T15:08:53ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2350319The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective studyFei Xin0Yan-Hui Yu1Xu-Liang Shen2Guo-Xiang Zhang3Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, People’s Republic of ChinaDepartment of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, People’s Republic of ChinaDepartment of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, People’s Republic of ChinaDepartment of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, People’s Republic of ChinaObjectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML, (including AML patients with treatment-related and ELN-adverse risk disease (n = 50)). These patients were treated with venetoclax and hypomethylating agents and HAG regimens, respectively.Results: Twenty-nine patients newly diagnosed with acute myeloid leukemia were treated with VEN-HMA (venetoclax-hypomethylating agent), while 23 patients were treated with HAG. The median age of the VEN-HMA group was 70 years, while the HAG group had a median age of 69 years. The VEN-HMA group achieved a significantly higher rate of complete remission (82.7%) compared to the cohort treated with the HAG regimen (21.7%) (P < 0.001). At the same time, the VEN-HMA group exhibited a significant survival advantage compared to the HAG treatment group(HR = 0.328, 95%CI: 0.158-0.683, P = 0.003).In patients with relapsed and refractory acute myeloid leukaemia, 43.8% of patients in the VEN-HMA treatment group achieved complete remission, which was similar to the 50% in the HAG treatment group (P > 0.99). The median overall survival was similar between the VEN-HMA and HAG groups, with 4 and 3.67 months, respectively (P = 0.290).Conclusions: In conclusion, our analyses indicated that VEN-HMA resulted in better therapeutic outcomes compared to HAG for newly diagnosed AML patients, with higher rates of complete remission and overall survival. In relapsed/refractory AML patients, there was no significant difference in the efficacy of the two treatments and further studies with larger sample sizes are warranted.https://www.tandfonline.com/doi/10.1080/16078454.2024.2350319Acute myeloid leukemiavenetoclaxHAG regimencomplete remissionoverall survivalnewly diagnosed |
spellingShingle | Fei Xin Yan-Hui Yu Xu-Liang Shen Guo-Xiang Zhang The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study Hematology Acute myeloid leukemia venetoclax HAG regimen complete remission overall survival newly diagnosed |
title | The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study |
title_full | The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study |
title_fullStr | The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study |
title_full_unstemmed | The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study |
title_short | The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study |
title_sort | efficacy of the combination of venetoclax and hypomethylating agents versus hag agents in patients with acute myeloid leukemia a retrospective study |
topic | Acute myeloid leukemia venetoclax HAG regimen complete remission overall survival newly diagnosed |
url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2350319 |
work_keys_str_mv | AT feixin theefficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy AT yanhuiyu theefficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy AT xuliangshen theefficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy AT guoxiangzhang theefficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy AT feixin efficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy AT yanhuiyu efficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy AT xuliangshen efficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy AT guoxiangzhang efficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy |